New Study Hopes to Improve Early Detection of Mesothelioma

Researchers in Germany have developed a novel blood test for mesothelioma cancer that could lead to earlier detection of the disease and a better prognosis for patients. The test involves calretinin, a blood-based protein that is overexpressed when mesothelioma tumors cells are present. The advancement stems from a study using a new enzyme-linked immunosorbent assay (ELISA) for detecting the biomarker more effectively. In the past, mesothelioma has been difficult to diagnose. It’s mostly accomplished with a combination of invasive tissue biopsies and detailed imaging tests after symptoms become obvious. A reliable blood test would make the process much easier, allowing those at high risk for the disease to be monitored regularly, likely leading to disease discovery in its infancy when it is more manageable. “It might be quite the advantage when it comes to treatment,” biochemist Dr. Georg Johnen, the lead researcher in the German study, told Asbestos.com. “This might allow you to see elevated marker levels well before you have symptoms.” Making Long-Term Survival Possible Occupational exposure to asbestos is the primary cause of mesothelioma, a rare and aggressive cancer with a long latency period (20-50 years). The majority of cases are not diagnosed until after the disease has spread, limiting treatment options. Getting an accurate diagnosis today often takes many months and a variety of tests. Long-term survival is rare. Less than 25 percent o...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: biomarkers for mesothelioma calretinin assay epithelioid mesothelioma Georg Johnen Mesomark blood assay mesothelioma cancer research mesothelioma cancer treatment Source Type: news

Related Links:

Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer. The long latency from asbestos exposure to MPM development, as well as the absence of early symptoms, lead to late diagnosis and very poor prognosis, with a life expectancy of 9-18 months from diagnosis [1]. Only a small number of patients is suitable for multimodal therapy, including surgery, and the majority of patients receive palliative chemotherapy.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The Princess Margaret Cancer Center in Toronto has moved from SMART to SMARTER with the recent launch of its latest clinical trial for pleural mesothelioma patients. SMARTER is the acronym for Surgery for Mesothelioma After Radiation Therapy using Extensive pleural Resection, which also describes the latest clinical trial. The phase I clinical trial is an unconventional approach to treatment of mesothelioma: Find the maximum tolerated dosage of hypofractionated radiation to stimulate the immune system before aggressive surgery. It comes on the heels of the SMART protocol, which stands for Surgery for Mesothelioma After Rad...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is an aggressive and invariably fatal cancer of the pleural surface that is associated with asbestos exposure [1]. MPM is usually detected at an advanced stage, therefore treatment options are limited to systemic chemotherapy with cisplatin and pemetrexed as the mainstay of palliative treatment for most patients [2]. Prognosis is generally poor for MPM, with a median survival of 12 months in patients treated with pemetrexed and cisplatin chemotherapy [3] but can be very variable, with around 5% of patients surviving more than 5 years [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Doctors at the Princess Margaret Cancer Center in Toronto are studying the use of hypofractionated radiation to increase the effectiveness of immunotherapy for patients with mesothelioma. They are expected to launch soon a clinical trial that will add an immunotherapy combination to the high-dose radiation and aggressive surgery mix that has been so successful in Toronto. “There are a lot of questions that still need to be answered, but if I was a betting man, I’d lay odds on it [working well],” Dr. John Cho of the cancer center’s clinical research unit, told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Aggressive surgery for the treatment of malignant pleural mesothelioma is being underutilized, costing patients significant survival time, according to a recent study. Researchers found mesothelioma patients from all three histological subtypes — epithelioid, biphasic and sarcomatoid — can benefit from surgery, despite a reluctance to perform it today. The National Comprehensive Cancer Network (NCCN), a nationwide alliance of leading cancer centers, encourages surgery only for epithelioid patients. This eliminates the option for almost 40 percent of those diagnosed with mesothelioma. “Surgery is underutil...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, which is often causally associated with asbestos exposure. Given the long latency period between asbestos exposure and MPM development and because asbestos is still being used in some countries, MPM will remain a global health issue for decades to come [1]. Although improvements in outcome have been observed with the advent of -palliative- chemotherapy, overall survival of patients plateaus at a median of one year [2]. Amongst others, this dismal prognosis can be attributed to difficulties in (early) diagnosis, lack of effective treatment and treatment monitoring.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: The overall strength of the evidence gathered in this review is low and there is a lack of available evidence to support the use of radical multimodality therapy in routine clinical practice (particularly as one trial suggests greater harm). Given the added cost of multimodality treatment and the possible increase in risk of adverse effects, the lack of evidence of their effectiveness probably means that these interventions should currently be limited to clinical trials alone. PMID: 29309720 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Earlier palliative care for patients with pleural mesothelioma failed to improve quality of life or extend survival time in a recent study presented at the World Conference on Lung Cancer in Yokohama, Japan. The randomized control study took place in Australia and the United Kingdom, disputing an earlier recommendation by the American Society of Clinical Oncology (ASCO) that called for expanding palliative care for mesothelioma patients. “Blindly offering palliative care to all, that doesn’t appear to be a benefit,” Dr. Fraser Brims, study presenter from Curtin University in Perth, Australia, told Asbest...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: American Society of Clinical Oncology Curtin University Dr. Fraser Brims epithelioid GHQ-12 Institute for Respiratory Health mesothelioma palliative care Perth Australia pleural mesothelioma quality-of-life variables Sir Charles Gardne Source Type: news
This article summarises the epidemiology and pathogenesis of malignant pleural mesothelioma, before describing some key factors in the patient experience and outlining common symptoms. Diagnostic approaches are reviewed, including imaging techniques and the role of various biomarkers. Treatment options are summarised, including the importance of palliative care and methods of controlling pleural effusions. The evidence for chemotherapy, radiotherapy and surgery is reviewed, both in the palliative setting and in the context of trimodality treatment. An algorithm for managing malignant pleural effusion in malignant pleural m...
Source: European Respiratory Review - Category: Respiratory Medicine Authors: Tags: Lung cancer Pleural Diseases Source Type: research
More News: Accidents | Asbestosis | Biochemistry | Cancer | Cancer & Oncology | Chemotherapy | Environmental Health | Food and Drug Administration (FDA) | Insurance | Lung Cancer | Mesothelioma | Occupational Health | Palliative | Study